Seroepidemiology of hepatitis E virus infection in patients undergoing maintenance hemodialysis: Systematic review and meta-analysis.
hemodialysis
hepatitis E virus
meta-analysis
seroprevalence
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
01
03
2020
revised:
28
03
2020
accepted:
24
04
2020
pubmed:
30
4
2020
medline:
8
10
2021
entrez:
30
4
2020
Statut:
ppublish
Résumé
Patients undergoing regular hemodialysis (HD) are at an extreme risk of acquiring bloodstream infections compared to the general population. Hepatitis E virus (HEV) infection is an important emerging health issue in these patients. To date, numerous studies have investigated the seroprevalence of HEV among HD patients across the world; however, the data are conflicting. The present study aimed to measure the exposure rate of HD patients to HEV infection by estimating the overall seroprevalence of HEV in this high-risk group. A systematic literature search was carried out using five electronic databases from inception to January 10, 2020, with standard keywords. Pooled seroprevalence estimates with 95% confidence intervals (CIs) were calculated using a random intercept logistic regression model. The seroprevalence of HEV increased from 6.6% between the years of 1994 and 2000 to 11.13% from 2016 to 2020. Blood transfusion was associated with a nearly 2-fold increase in the rate of HEV seropositivity (OR = 1.99; 95% CI: 1.50-2.63, P < .0001, I
Identifiants
pubmed: 32348032
doi: 10.1111/1744-9987.13507
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4-15Informations de copyright
© 2020 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.
Références
World Health Organization. Hepatitis E. Available from: http://www.who.int/en/news-room/fact-sheets/detail/hepatitis-e. Accessed July 8, 2019
Pérez-Gracia MT, García M, Suay B, Mateos-Lindemann ML. Current knowledge on hepatitis E. J Clin Transl Hepatol. 2015;3:117-126.
Hadifar S, Sedighi M, Mostafaei S, et al. Prevalence of hepatitis E infection in the general population of Iran: A systematic review and meta-analysis. Future Virol. 2017;12:227-236.
Himmelsbach K, Bender D, Hildt E. Life cycle and morphogenesis of the hepatitis E virus. Emerg Microbes Infect. 2018;7:1-12.
Sue PK, Pisanic N, Heaney CD, et al. Hepatitis E virus infection among solid organ transplant recipients at a north American transplant center. Open Forum Infect Dis. 2016;3:1-8.
Suri RS, Li L, Nesrallah GE. The risk of hospitalization and modality failure with home dialysis. Kidney Int. 2015;88:360-368.
Ferraz FHRP, Rodrigues CIS, Gatto GC, NMd S. Differences and inequalities in relation to access to renal replacement therapy in the BRICS countries. Cien Saude Colet. 2017;22:2175-2185.
Ghorbani NR, Djalalinia S, Modirian M, et al. Prevalence of hepatitis C infection in Iranian hemodialysis patients: An updated systematic review and meta-analysis. J Res Med Sci. 2017;22:1-10.
Ashkani-Esfahani S, Alavian SM, Salehi-Marzijarani M. Prevalence of hepatitis C virus infection among hemodialysis patients in the middle-east: A systematic review and meta-analysis. World J Gastroenterol. 2017;23:151-166.
Bernieh B. Viral hepatitis in hemodialysis: An update. J Transl Int Med. 2015;3:93-105.
Tavakoli A, Moghoofei M, Mostafaei S, Ghaffari H, Monavari SH, Alavian SM. Prevalence of hepatitis B surface antigen among hemodialysis patients from middle eastern countries: A systematic review and meta-analysis. Future Virol. 2017;12:309-318.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med. 2009;151:264-269.
Moosazadeh M, Nekoei-moghadam M, Emrani Z, Amiresmaili M. Prevalence of unwanted pregnancy in Iran: A systematic review and meta-analysis. Int J Health Plann Manage. 2014;29:1-14.
Stijnen T, Hamza TH, Özdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med. 2010;29:3046-3067.
Newcombe RG. Two-sided confidence intervals for the single proportion: Comparison of seven methods. Stat Med. 1998;17:857-872.
Cox D. The continuity correction. Biometrika. 1970;57:217-219.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: A practical tutorial. Evid Based Ment Health. 2019;22:153-160.
Psichogiou M, Vaindirli E, Tzala E, et al. Hepatitis E virus (HEV) infection in haemodialysis patients. Nephrol Dial Transplant. 1996;11:1093-1095.
El Sayed ZM, Magdy Abd El Razek H, Magdy Abd El Razek M. P46: Hepatitis E viral seroprevalence among multiple transfused Egyptian children. J Viral Hepat. 2013;20:40-41.
Halfon P, Ouzan D, Chanas M, et al. High prevalence of hepatitis E virus antibody in haemodialysis patients. Lancet. 1994;344:746.
Knödler B, Hiller J, Löliger C, Kühnl L. Hepatitis e antibodies in blood donors, hemodialysis patients and in normal people. Beitr Infusionsther Transfusionsmed. 1994;32:124-127.
Buti M, Jardí R, Cotrina M, et al. Hepatitis E virus infection in acute hepatitis in Spain. J Virol Methods. 1995;55:49-54.
Cengiz K, Özyilkan E, Coşar AM, Günaydin M. Seroprevalence of hepatitis E in hemodialysis patients in Turkey. Nephron. 1996;74:730.
Fabrizi F, Lunghi G, Bacchini G, et al. Low prevalence of hepatitis E virus antibody in haemodialysis patients: A seroepidemiological study. G Ital Nefrol. 1996;13:227-232.
Gessoni G, Manoni F. Hepatitis E virus infection in north-East Italy: Serological study in the open population and groups at risk. J Viral Hepat. 1996;3:197-202.
Guiserix J, Finielz P, Ramdane M, Rajaonarivelo P. Hepatitis E seroprevalence in dialysis in southern Reunion Island. Nephron. 1996;74:230.
Fabrizi F, Lunghi G, Bacchini G, Corti M, Pagano A, Locatelli F. Hepatitis E virus infection in haemodialysis patients: A seroepidemiological survey. Nephrol Dial Transplant. 1997;12:133-136.
Parana R, Cotrim H, Cortey-Boennec M, Trepo C, Lyra L. Prevalence of hepatitis E virus IgG antibodies in patients from a referral unit of liver diseases in Salvador, Bahia, Brazil. Am J Trop Med Hyg. 1997;57:60-61.
Abdel SH, El-Din MS, El-Din ME. A high hepatitis E virus (HEV) seroprevalence among unpaid blood donors and haemodialysis patients in Egypt. J Egypt Public Health Assoc. 1998;73:165-179.
Arinsoy T, Yilmaz M, Derici U, Sindel S. Prevalence of hepatitis E virus antibody in hemodialysis patients. Nephron. 1998;80:85.
Gessoni G, Rusca A, Valverde S, Antico F, Manoni F. Circulating anti-HEV antibodies: An Italian retrospective sero-epidemiological study. Eur J Lab Med. 1998;6:41-46.
Dalekos G, Zervou E, Elisaf M, et al. Antibodies to hepatitis E virus among several populations in Greece: Increased prevalence in an hemodialysis unit. Transfusion. 1998;38:589-595.
Sylvan SP, Jacobson SH, Christenson B. Prevalence of antibodies to hepatitis E virus among hemodialysis patients in Sweden. J Med Virol. 1998;54:38-43.
Agarwal S, Irshad M, Dash S. Prevalence of antibodies against hepatitis E virus in haemodialysis patients in India. Nephron. 1999;81:448.
Kilic H, Utas C, Oymak O, Unal A, Karagoz S, Sahin I. Investigation of hepatitis E virus antibodies in sera obtained from hemodialysis patients and healthy donors. Erciyes Tip Derg. 1999;21:80-82.
Mateos ML, Camarero C, Lasa E, Teruel JL, Mir N, Baquero F. Hepatitis E virus: Relevance in blood donors and risk groups. Vox Sang. 1999;76:78-80.
Trinta KS, Liberto MIM, De Paula VS, Yoshida CF, Gaspar A. Hepatitis E virus infection in selected Brazilian populations. Mem Inst Oswaldo Cruz. 2001;96:25-29.
Irshad M, Peter S, Agarwal S, Choudhary P. Viral hepatitis in multiple blood transfused patients treated at a referral Hospital of Delhi, India. Int Med J. 2002;9:57-60.
Ayoola E, Want M, Gadour M, Al-Hazmi M, Hamza M. Hepatitis E virus infection in haemodialysis patients: A case-control study in Saudi Arabia. J Med Virol. 2002;66:329-334.
Kiesslich D, Rocha J Jr, Crispim M. Prevalence of hepatitis E virus antibodies among different groups in the Amazonian basin. Trans R Soc Trop Med Hyg. 2002;96:215.
Ding X, Li T-C, Hayashi S, et al. Present state of hepatitis E virus epidemiology in Tokyo, Japan. Hepatol Res. 2003;27:169-173.
Mitsui T, Tsukamoto Y, Yamazaki C, et al. Prevalence of hepatitis E virus infection among hemodialysis patients in Japan: Evidence for infection with a genotype 3 HEV by blood transfusion. J Med Virol. 2004;74:563-572.
Stefanidis I, Zervou E, Rizos C, et al. Hepatitis E virus antibodies in hemodialysis patients: An epidemiological survey in Central Greece. Int J Artif Organs. 2004;27:842-847.
Lee C-C, Shih Y-L, Laio C-S, et al. Prevalence of antibody to hepatitis E virus among haemodialysis patients in Taiwan: Possible infection by blood transfusion. Nephron Clin Pract. 2005;99:c122-c1277.
Taremi M, Khoshbaten M, Gachkar L, EhsaniArdakani M, Zali M. Hepatitis E virus infection in hemodialysis patients: A seroepidemiological survey in Iran. BMC Infect Dis. 2005;5:1-4.
Kikuchi K, Yoshida T, Kimata N, Sato C, Akiba T. Prevalence of hepatitis E virus infection in regular hemodialysis patients. Ther Apher Dial. 2006;10:193-197.
Pourahmad M, Sotoodeh AR, Nasiri H. Hepatitis E virus infection in hemodialysis patients: A seroepidemiological survey in Jahrom, southern Iran. Hepat Mon. 2009;9:232-235.
Uçar E, Cetin M, Kuvandik C, Helvaci MR, Güllü M, Hüzmeli C. Hepatitis E virus seropositivity in hemodialysis patients in Hatay province, Turkey. Mikrobiyol Bul. 2009;43:299-302.
Mina P, Georgiadou SP, Rizos C, Dalekos GN, Rigopoulou EI. Prevalence of occult hepatitis B virus infection in haemodialysis patients from Central Greece. World J Gastroenterol. 2010;16:225-231.
Khameneh ZR, Sepehrvand N, Masudi S. Seroprevalence of hepatitis E among Iranian renal transplant recipients. Hepat Mon. 2011;11:646-651.
Harrison A, Scobie L, Crossan C, et al. Hepatitis E seroprevalence in recipients of renal transplants or haemodialysis in Southwest England: A case-control study. J Med Virol. 2013;85:266-271.
Mobaien A, Mohammadi R, Sorouri R, Sadeghi K. Hepatitis E virus seroprevalence in haemodialysis patients in Zanjan Province, Islamic Republic of Iran. East Mediterr Health J. 2013;19:608-612.
Scotto G, Martinelli D, Centra M, et al. Epidemiological and clinical features of HEV infection: A survey in the district of Foggia (Apulia, southern Italy). Epidemiol Infect. 2014;142:287-294.
Zekavat OR, Makarem A, Karami MY, Amanat A, Mohandes M, Habibagahi M. Serological investigation for hepatitis E virus infection in the patients with chronic maintenance hemodialysis from southwest of Iran. Asian J Transf Sci. 2013;7:21-25.
Ben-Ayed Y, Hannachi H, Ben-Alaya-Bouafif N, Gouider E, Triki H, Bahri O. Hepatitis E virus seroprevalence among hemodialysis and hemophiliac patients in Tunisia (North Africa). J Med Virol. 2015;87:441-445.
Kelishadi M, Mojerloo M, Moradi A, et al. GB virus C viremia and anti-E2 antibody response among hemodialysis patients in Gorgan, Iran. Jundishapur J Microbiol. 2014;7:1-7.
Mousavi SSB, Motemednia F, Mousavi MB. Epidemiology of hepatitis e virus infection in patients on chronic hemodialysis. Jundishapur J Microbiol. 2014;7:1-4.
Alavian SM, Ataei B, Ebrahimi A, et al. Anti-hepatitis E antibody in hemodialysis patients in Isfahan, Iran: Prevalence and risk factors. Hepat Mon. 2015;15:1-5.
Zaki MES, Abdelsalam M, Anbar NH, El-deek BS. Prevalence of hepatitis E virus among hemodialysis patients: One Egyptian center study. IJHSR. 2015;5:65-72.
Eini P, Mamani M, Javani M. Seroprevalence of hepatitis e among hemodialysis patients: A report from Hamadan, Iran. Hepat Mon. 2015;15:1-4.
Scotto G, Aucella F, Grandaliano G, et al. Hepatitis E in hemodialysis and kidney transplant patients in south-East Italy. World J Gastroenterol. 2015;21:3266-3273.
Daniel Debes J, Martinez Wassaf M, Belen Pisano M, et al. Hepatitis E infection in Argentina, from immunocompetent to immunocompromised. Am J Trop Med Hyg. 2017;95:240-241.
Hajiahmadi N, Moradi A, Vakili MA, et al. Hepatitis E virus Seroprevalence and viremia in hemodialysis and HIV infected patients in Iran. Iran J Virol. 2016;10:12-17.
Pisano MB, Balderramo D, Wassaf MM, et al. Hepatitis E virus infection in patients on dialysis and in solid organ transplant recipients in Argentina: Exploring associated risk factors. Arch Virol. 2017;162:787-792.
Naziri H, Tahamtan A, Moradi A, Tabarraei A. Evaluation of anti-hepatitis E virus antibody among hemodialysis patients in Gorgan, north of Iran. Iran J Virol. 2016;10:13-18.
Ricco G, Bonino F, Lanza M, et al. New immunoassays for total, IgA and IgM antibodies against hepatitis E virus: Prevalence in Italian blood donors and patients with chronic liver or kidney diseases. Dig Liver Dis. 2016;48:536-541.
Yılmaz N, Çifci A, Balcı M, et al. The seroprevalance of hepatitis E, hepatitis G and TTV in haemodialysis patients. Ortadoğu tıp derg. 2017;9(1):6-11.
Sheng X, Wang N. Epidemiology of hepatitis E virus infection among hemodialysis patents in a single center in Shanghai: MP734. Nephrol Dial Transplant. 2017;32:iii703-iii704.
Altuglu I, Yasar M, Zeytinoglu A, Ozkahya M. Anti-hepatitis E antibody in hemodialysis patients. Turk Neph Dial Transpl. 2018;27:117-118.
de Oliveira JMNS, de Freitas NR, Teles SA, et al. Prevalence of hepatitis E virus RNA and antibodies in a cohort of kidney transplant recipients in Central Brazil. Int J Infect Dis. 2018;69:41-43.
Kuznetsova TV, Ivanova-Pozdejeva A, Reshetnjak I, et al. Hepatitis E virus infection in different groups of Estonian patients and people who inject drugs. J Clin Virol. 2018;104:5-10.
Lemos AS, Ribeiro CRdA, Barbosa JR et al. Hepatitis E virus prevalence among chronic kdney disease hemodialysis-dependent patients. VI International Symposium on Immunobiologicals; 2019:155.
Mrzljak A, Dinjar-Kujundzic P, Knotek M, et al. Seroepidemiology of hepatitis E in patients on haemodialysis in Croatia. Int Urol Nephrol. 2020;52:371-378.
Sharif MR, Chitsazian Z, Moosavian M, et al. Immune disorders in hemodialysis patients. Iran J Kidney Dis. 2015;9:84-96.
Ito T, Maekawa H, Sakurada M, et al. Risk factors for postoperative complications in patients on maintenance hemodialysis who undergo abdominal surgery. Asian J Surg. 2016;39:211-217.
Luma HN, Halle MP, Eloumou SAFB, et al. Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses among haemodialysis patients in two newly opened centres in Cameroon. Pan Afr Med J. 2017;27:1-10.
Kamar N, Izopet J, Dalton HR. Chronic hepatitis E virus infection and treatment. J Clin Exp Hepatol. 2013;3:134-140.
Haffar S, Bazerbachi F, Leise M, et al. Systematic review with meta-analysis: The association between hepatitis E seroprevalence and haemodialysis. Aliment Pharmacol Ther. 2017;46:790-799.
Hosseini-Moghaddam SM, Zarei A, Alavian SM, Mansouri M. Hepatitis E virus infection: A general review with a focus on hemodialysis and kidney transplant patients. Am J Nephrol. 2010;31:398-407.
Vina-Rodriguez A, Schlosser J, Becher D, Kaden V, Groschup MH, Eiden M. Hepatitis E virus genotype 3 diversity: Phylogenetic analysis and presence of subtype 3b in wild boar in Europe. Viruses. 2015;7:2704-2726.
Gardinali NR, Guimarães JR, Melgaco JG, et al. Cynomolgus monkeys are successfully and persistently infected with hepatitis E virus genotype 3 (HEV-3) after long-term immunosuppressive therapy. PLoS One. 2017;12:1-22.
Park W-J, Park B-J, Ahn H-S, et al. Hepatitis E virus as an emerging zoonotic pathogen. J Vet Sci. 2016;17:1-11.
Thiry D, Rose N, Mauroy A, et al. Susceptibility of pigs to zoonotic hepatitis E virus genotype 3 isolated from a wild boar. Transbound Emerg Dis. 2017;64:1589-1597.
Zhu F-C, Zhang J, Zhang X-F, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: A large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet. 2010;376:895-902.